Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Estrella Immunopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Estrella Immunopharma's regulatory disclosures and financial reporting.
Estrella Immunopharma, Inc. (ESLA) reported that CEO and director Liu Cheng exercised stock options for 100,000 shares of common stock on 2026-08-25 at an exercise price of $0.815 per share. Following the exercise, Cheng directly holds 397,437 shares of common stock and 900,000 incentive stock options related to this award remain outstanding.
The options were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan, with 25% immediately exercisable at grant and the remainder vesting in equal monthly installments of 1/48th of the total award; the options exercised were vested.
Estrella Immunopharma, Inc. (ESLA) reported that its Chief Financial Officer, Jiandong Xu, exercised 100,000 Incentive Share Options on 2026-08-18 at an exercise price of $0.815 per share, receiving an equal number of common shares. Following the exercise, Xu directly holds 365,488 shares of common stock and 390,796 incentive share options. The options exercised were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan and were vested as to the shares exercised.
Estrella Immunopharma, Inc. (ESLA) reported that on August 17, 2026 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement, after trading below $1.00 for 30 consecutive business days from July 6 through August 14, 2026. The stock continues to trade on the Nasdaq Capital Market under “ESLA” while the company has 180 calendar days, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days, or longer at Nasdaq’s discretion. Estrella may use tools such as a reverse stock split, which would need to be completed at least ten business days before the compliance deadline, and could receive an additional 180-day period if it meets other Nasdaq listing standards. The company plans to monitor its share price and evaluate options, but states there is no assurance it will regain or maintain compliance.
Armistice Capital, LLC and Steven Boyd report a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. common stock. They report beneficial ownership of 2,051,409 shares of common stock with no sole voting or dispositive power and shared voting and dispositive power over all 2,051,409 shares. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these securities. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.
Estrella Immunopharma, Inc. is a clinical-stage biotech focused on T‑cell therapies EB103 and EB104 and has not generated product revenue. For the quarter ended June 30, 2026 it reported a net loss of $2.3 million, and a $4.6 million net loss for the six‑month period.
Six‑month research and development expense was $2.8 million and general and administrative expense $1.5 million, largely driven by clinical trial services from related‑party Eureka and professional fees. A $0.3 million non‑cash loss arose from remeasurement of derivative liabilities tied to True‑Up share features.
Liquidity is constrained: cash and cash equivalents were $146,670 at June 30, 2026 versus current liabilities of $9.3 million, including about $8.3 million owed to Eureka under the STARLIGHT‑1 Statement of Work. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Estrella Immunopharma, Inc. reported the results of its Combined 2025/2026 Annual Meeting of Stockholders held virtually on June 29, 2026. Stockholders voted on one proposal: ratification of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 43,034,228 shares of common stock outstanding and entitled to vote as of May 20, 2026, the record date. Holders of 30,351,608 shares were present or represented by proxy, representing approximately 70.5% of the eligible shares and establishing a quorum. Stockholders ratified the appointment of Macias Gini & O’Connell LLP with 30,351,203 votes for, 400 votes against, 5 abstentions and no broker non-votes.
Estrella Immunopharma, Inc. is holding a virtual Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026 at 10:00 a.m. Eastern Time, asking stockholders to ratify the appointment of Macias Gini & O’Connell LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
The record date is May 20, 2026, when 43,034,228 shares of common stock were outstanding and entitled to vote. The proxy statement explains online participation and advance question procedures and shows that Eureka Therapeutics, Inc. beneficially owns 58.7% of the common stock, with Armistice Capital, LLC at 9.9%.
Estrella Immunopharma reported a Schedule 13G filing showing Armistice Capital, LLC and Steven Boyd as reporting persons. The filing states 4,280,375 shares are beneficially owned, representing 9.99% of the common stock (CUSIP 297584104) as disclosed with an ownership date tied to 03/31/2026. The filing explains Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., which is the direct holder, and that voting and dispositive power are shared through an Investment Management Agreement. The filing is signed by Steven Boyd on 05/15/2026.
Estrella Immunopharma, Inc. filed an amended annual report to add detailed disclosures on board composition, executive compensation, ownership and auditor matters for the period ended December 31, 2025. The filing confirms a seven‑member board, three key committees, and independence status for several directors.
The amendment shows the CEO and CFO each earned salary of $250,962 in 2025, with prior equity awards under the 2023 Omnibus Incentive Plan. As of March 12, 2026, 42,665,228 common shares were outstanding and Eureka Therapeutics, Inc. beneficially owned about 59.3% of the stock, making Estrella a controlled company under Nasdaq rules.
Estrella Immunopharma’s Chief Financial Officer, Jiandong Xu, reported a series of open-market purchases of the company’s common stock. On October 7, 2025, he bought 1,000 shares at $1.33 per share, bringing his direct holdings to 265,488 shares.
Earlier, on September 11, 2025, Xu purchased 100 shares at $1.04 per share. On September 22, 2025, 1,000 shares were purchased at $1.16 per share and are held by his spouse, totaling 16,700 shares in that account. The filing states Xu disclaims beneficial ownership of the spouse-held shares for Section 16 and other purposes.